Prosensa files for IPO

Prosensa B.V. (Leiden, the Netherlands) filed to raise up to $60 million in an IPO on NASDAQ underwritten by JPMorgan; Citigroup; Leerink; Wedbush; and KBC Securities. Last month, partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reported that continuous dosing with once-weekly subcutaneous drisapersen ( PRO051, GSK2402968) met the primary in a Phase IIb trial to treat Duchenne muscular dystrophy (DMD), while intermittent dosing missed the endpoint (see BioCentury, April 15, 2013). ...